Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's performance in the first half of 2025 met expectations, with a revenue of 266 million (up 20.50% year-on-year) and a net profit attributable to shareholders of 74 million (up 5.52% year-on-year) [8] - The main business showed strong performance, with the medical endoscope equipment sector generating 207 million in revenue (up 17.72%), accounting for 78.28% of main business revenue [8] - The company is focusing on expanding its production capabilities in Thailand to mitigate the impact of tariffs on its business, with significant progress in developing next-generation endoscope systems [8] Financial Summary - Revenue projections for 2025-2027 are 542.15 million, 639.44 million, and 755.09 million respectively, with year-on-year growth rates of 22.43%, 17.95%, and 18.09% [1][9] - Net profit attributable to shareholders is projected to be 175.31 million, 213.04 million, and 262.06 million for 2025-2027, with growth rates of 29.52%, 21.53%, and 23.01% respectively [1][9] - The latest diluted EPS is expected to be 1.46, 1.78, and 2.19 for 2025-2027, with corresponding P/E ratios of 32.19, 26.49, and 21.54 [1][9]